NCT00001020View on ClinicalTrials.gov

A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

Not specified

Study Completion Date

February 28, 1995

Conditions
HIV Infections
Interventions
BIOLOGICAL

rgp120/HIV-1IIIB

BIOLOGICAL

rgp120/HIV-1MN

Trial Locations (3)

19104

Univ of Pennsylvania at Philadelphia, Philadelphia

63104

St Louis Univ School of Medicine, St Louis

981050371

Children's Hospital & Medical Center / Seattle ACTU, Seattle

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH